TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04540991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gingiva former placement
Description: Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gingiva former placement
Description: Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Collecting gingival epithelial cellsusing the swab technique
Description: Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Collecting gingival epithelial cellsusing the swab technique
Description: Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
Study: NCT03523520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone Bromide 150 mg Oral Tablet
Description: Methylnaltrexone Bromide 150 mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1
Description: Methylnaltrexone Bromide 12 MG Subcutaneous Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol 25 MG Oral Tablet
Description: Naloxegol 25 MG Oral Tablet
Study: NCT02165449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
Study: NCT03358927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Fast-Track Care
Description: Eligible for fast-track care at enrollment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deferred Fast-Track Care
Description: Eligible for fast-track care after 6 months on ART
Study: NCT02841761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midalozam
Description: Syrup for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midalozam
Description: Syrup for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Capsules for oral use
Study: NCT00908570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol
Description: 4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream
Study: NCT04416282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Injection terlipressin 2 mg/24 hours infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: i/v albumin 1g/Kg/day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: i/v albumin 1g/Kg/day
Study: NCT01215136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
Study: NCT02352701

Intervention type: DRUG
Intervention: Noltec tab. 10mg
Description: Ilaprazole 10mg BID dosage form : delayed release tablet

Intervention type: DRUG
Intervention: Chongkundang Amoxicillin Cap. 500mg
Description: Amoxicillin 1000mg, BID dosage form : capsule

Intervention type: DRUG
Intervention: Cravit Tab. 500mg
Description: Levofloxacin 500mg, BID dosage form : film coated tablet
Study: NCT02653248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
Study: NCT01526655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal total hysterectomy
Description: Abdominal total hysterectomy through a low transverse abdominal wall incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted laparoscopic hysterectomy
Description: Robot assisted laparoscopic total hysterectomy
Study: NCT02614924

Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible fibreoptic scope
Description: Patient intubated using fibreoptic scope
Study: NCT02391389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP or PPV during DCC
Description: CPAP or PPV is provided during delayed cord clamping
Study: NCT03876678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius AP-32
Description: Taking 1 probiotic capsule two times everyday for 7 days.
Study: NCT02614924

Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible fibreoptic scope
Description: Patient intubated using fibreoptic scope

Intervention type: DEVICE
Group type: OTHER
Intervention: Pentax AWS videolaryngoscope
Description: Patient intubated using Pentax AWS videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: Pentax AWS videolaryngoscope
Description: Patient intubated using Pentax AWS videolaryngoscope
Study: NCT00501072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose monitoring System (RT-CGMS)
Study: NCT03726060

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months

Intervention type: OTHER
Group type: OTHER
Intervention: test group
Description: In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
Study: NCT01515423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 175 mg eq.
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT01489345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: 30 mg to 100 mg QD at a multiple dose, and 21 days duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2952 Matching Placebo
Description: 30 mg to 100 mg QD at a multiple dose, and 21 days duration
Study: NCT04301024

Intervention type: OTHER
Intervention: assessing the nitrous oxide misuse
Description: assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
Study: NCT03014570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIT-4-BPSD
Description: This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
Study: NCT01515423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 263 mg eq.
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 350 mg eq.
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 525 mg eq.
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Study: NCT00279916

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo nasal spray
Description: Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily.
Study: NCT04090411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Induction- PF-06480605 50 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction- PF-06480605 150 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction- PF-06480605 150 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction- PF-06480605 450 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction- PF-06480605 450 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction- PF-06480605 450 mg SC Q4W
Description: PF-06480605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction- Placebo SC Q4W
Description: 0 mg Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction- Placebo SC Q4W
Description: 0 mg Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction- Placebo SC Q4W
Description: 0 mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 50 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chronic- PF-06480605 50 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 50 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 50 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 150 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 150 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 150 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 450 mg SC Q4W
Description: PF-06480605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic- PF-06480605 450 mg SC Q4W
Description: PF-06480605
Study: NCT00798525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argatroban
Description: Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lepirudin
Description: Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
Study: NCT03014570

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-only Control
Description: This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
Study: NCT03876678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subspecies lactis CP-9
Description: Taking 1 probiotic capsule two times everyday for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 placebo capsule two times everyday for 7 days.
Study: NCT03071874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a dual mTORC1/mTORC2 inhibitor
Study: NCT01673997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Metoprolol Succinate ER Tablets 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: Metoprolol Succinate ER Tablets 200 mg
Study: NCT03857633

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Whole Blood Samples
Description: 20ml EDTA whole blood samples - collected sequentially during study - max 8 time points

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Whole Blood Samples
Description: 20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
Study: NCT01428908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A+C+hib Conjugate Vaccine
Description: The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A+C+hib Conjugate Vaccine
Description: The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intramuscularly on the other arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intramuscularly on the other arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Vaccine
Description: The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Vaccine
Description: The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
Study: NCT00658177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 20mg to be taken 1 h prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04878861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the blind field
Description: Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
Study: NCT01520129

Intervention type: OTHER
Group type: OTHER
Intervention: Interpersonal and social rhythm therapy
Description: IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
Study: NCT03423732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CardioCell
Description: Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Study: NCT01308307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photorefraction
Description: photorefraction is a name of device.
Study: NCT02552030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cuff device (Omron HBP-1300-E Pro)
Description: Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPhone 4s
Study: NCT00180388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic vein harvesting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open vein harvesting
Study: NCT02273661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Ambisome®)
Description: An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An aerosol of isotonic saline x 1/ week will be administered during 6 months
Study: NCT02497183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: A repeat ultrasound exam following oral contrast material consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iodine based solution of oral contrast material
Description: A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
Study: NCT01774799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group